[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6221 followers
Created: 2025-07-28 03:32:12 UTC

Wockhardt’s Zaynich® Shows Promise Against Drug-Resistant Infections 🌍💊 | MCap XXXXXXXXX Cr

- Zaynich® (WCK 5222) treated a U.S. liver transplant patient infected with pan-drug resistant Pseudomonas and Klebsiella.
- Case published in Journal of Antimicrobial Chemotherapy - AMR on July 17, 2025.
- Patient showed improvement in XX days, remained infection-free after X weeks.
- Phase III trials completed; used in 50+ patients in India/U.S. under compassionate programs.
- Wockhardt has X FDA QIDP-designated antibiotics, with X already approved.
- Global workforce: ~2,900 employees; XX% of revenue from international markets.

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

![](https://pbs.twimg.com/media/Gw6iQrTXIAAMr7B.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1949674222466281959/c:line.svg)

**Related Topics**
[amr](/topic/amr)
[mcap](/topic/mcap)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1949674222466281959)